Seven Fleet Capital Management LP lifted its stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report) by 123.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,541 shares of the company’s stock after purchasing an additional 33,487 shares during the period. Seven Fleet Capital Management LP owned about 0.16% of Contineum Therapeutics worth $992,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently modified their holdings of the stock. Strs Ohio acquired a new stake in Contineum Therapeutics in the 1st quarter worth about $27,000. Qube Research & Technologies Ltd acquired a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $43,000. Marex Group plc acquired a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $45,000. Royal Bank of Canada lifted its position in shares of Contineum Therapeutics by 73.5% in the first quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after acquiring an additional 2,454 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Contineum Therapeutics in the second quarter valued at approximately $76,000.
Analyst Ratings Changes
Several analysts recently commented on CTNM shares. Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Friday, July 17th. Royal Bank Of Canada boosted their price target on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Finally, Morgan Stanley raised their target price on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $20.25.
Contineum Therapeutics Trading Down 5.0%
Shares of CTNM opened at $16.70 on Friday. Contineum Therapeutics, Inc. has a 12-month low of $8.60 and a 12-month high of $17.78. The firm has a market capitalization of $628.27 million, a P/E ratio of -9.65 and a beta of 0.75. The firm has a 50-day moving average price of $15.37 and a 200 day moving average price of $14.06.
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. Equities research analysts predict that Contineum Therapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Featured Stories
- Five stocks we like better than Contineum Therapeutics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
